论文部分内容阅读
目的:探讨孟鲁司特钠联合布地奈德联合治疗支气管哮喘急性发作的临床疗效。方法:选取我院自2015年1月至2016年1月收治的80例支气管哮喘患者作为观察对象,速记分为实验组和对照组,每组各有40例,对照组予常规对症治疗,实验组在对照组基础上加用孟鲁司特钠、布地奈德,观察比较两组患者治疗后的总有效率、肺功能及不良反应情况。结果:实验组治疗后的总有效率为97.5%,明显高于对照组的80.0%,两组疗效比较差异有统计学意义(P<0.05),且实验组的不良反应率为5.0%,明显低于对照组的17.5%,两组比较差异显著,具有统计学的意义,P<0.05。两组患者肺功能情况进行比较,差异有统计学的意义,P<0.05。结论:给予疗支气管哮喘患者采用孟鲁司特钠联合布地奈德进行治疗,可以提高疗效,有效缓解患者的临床症状。
Objective: To investigate the clinical efficacy of combination of montelukast and budesonide in the treatment of acute attack of bronchial asthma. Methods: Eighty patients with bronchial asthma admitted in our hospital from January 2015 to January 2016 were selected as experimental subjects. The shorthand was divided into experimental group and control group, 40 cases in each group. The control group was given conventional symptomatic treatment, and the experimental group On the basis of the control group, montelukast sodium and budesonide were added. The total effective rate, pulmonary function and adverse reactions of the two groups were observed and compared. Results: The total effective rate of the experimental group after treatment was 97.5%, which was significantly higher than that of the control group (80.0%), the difference between the two groups was statistically significant (P <0.05), and the adverse reaction rate was 5.0% in the experimental group Lower than 17.5% of the control group, the difference between the two groups was significant, with statistical significance, P <0.05. The lung function of two groups were compared, the difference was statistically significant, P <0.05. Conclusion: The treatment of patients with bronchial asthma with montelukast combined with budesonide can improve the curative effect and effectively alleviate the clinical symptoms of patients.